EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Eligibility for Germline Multigene Panel Testing in Breast Cancer: An Evaluation of Current Testing Criteria

Roxana Pintican, Nicoleta Antone Zenovia iD, Vlad Alexandru Gata iD, Natalia Moise, Andrei Roman iD, Carmen Lisencu, Adrian Pavel Trifa iD, Ovidiu Balacescu iD, Madalina Filip, Maria Miclaus, Andreea Catana iD, Catalin Vlad und 1 weitere

Diagnostics · 17.07.2026 · 16 (14) · 2244

DOI: 10.3390/diagnostics16142244 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diagnostics, online erschienen am 17.07.2026. Verfasst von Roxana Pintican und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Germline multigene testing is increasingly integrated into breast cancer care, but the ability of current eligibility frameworks to identify pathogenic variant carriers remains uncertain in real-world cohorts.

Methods

This retrospective observational study included 556 patients with histologically confirmed breast cancer who underwent germline multigene testing at a single oncology center. Testing eligibility was retrospectively assessed according to NCCN criteria, ESMO-based recommendations, and the ASBrS universal-testing recommendations. Family history up to third-degree relatives and surgical data were evaluated.

Results

Pathogenic variants were identified in 137 patients (24.6%), while variants of uncertain significance were reported in 310 patients (55.8%). NCCN criteria were fulfilled by 135 of 137 patients with pathogenic variants (98.5%), indicating high sensitivity but limited discriminatory capacity, as eligibility was also frequent among patients without pathogenic variants. ESMO-based criteria were met by 94 mutation-positive patients (68.6%) and were significantly associated with pathogenic variant status (p < 0.001; OR = 3.08, 95% CI: 2.05–4.65). Notably, 42.3% of pathogenic-variant-positive patients reported no family history of malignancy. Prophylactic surgery was documented in only 16.8% of patients with pathogenic variants.

Conclusions

NCCN criteria captured nearly all mutation-positive patients; ESMO-based criteria were more selective. The findings support broader access to germline testing before surgery.

Schlagwörter

Stichwörter der Autor:innen

BRCANCCNbreast cancergenetic criteriamultigene panel tests

Autor:innen und Institutionen

  • Department of Radiology, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
  • Breast Cancer Center, The Oncology Institute "Prof. Dr. Ion Chiricuta", 400015 Cluj-Napoca, Romania.
  • Department of Radiology, The Oncology Institute "Prof. Dr. Ion Chiricuta", 400015 Cluj-Napoca, Romania.
  • Department of Oncology, The Oncology Institute "Prof. Dr. Ion Chiricuta", 400015 Cluj-Napoca, Romania.
  • Department of Surgery, The Oncology Institute "Prof. Dr. Ion Chiricuta", 400015 Cluj-Napoca, Romania.
  • Center for Research and Innovation in Personalized Medicine of Respiratory Diseases, Discipline of Medical Genetics, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.

ORCID-Profile: Nicoleta Antone Zenovia, Vlad Alexandru Gata, Andrei Roman, Adrian Pavel Trifa, Ovidiu Balacescu, Andreea Catana, Patriciu Achimas-Cadariu

Zitieren

APA

Pintican, R., Zenovia, N. A., Gata, V. A., Moise, N., Roman, A., Lisencu, C., Trifa, A. P., Balacescu, O., Filip, M., Miclaus, M., Catana, A., Vlad, C., & Achimas-Cadariu, P. (2026). Real-World Eligibility for Germline Multigene Panel Testing in Breast Cancer: An Evaluation of Current Testing Criteria. Diagnostics, 16(14), 2244. https://doi.org/10.3390/diagnostics16142244

Vancouver

Pintican R, Zenovia NA, Gata VA, Moise N, Roman A, Lisencu C, et al. Real-World Eligibility for Germline Multigene Panel Testing in Breast Cancer: An Evaluation of Current Testing Criteria. Diagnostics. 2026;16(14):2244. doi:10.3390/diagnostics16142244

BibTeX
@article{Pintican2026,
  author = {Pintican, Roxana and Zenovia, Nicoleta Antone and Gata, Vlad Alexandru and Moise, Natalia and Roman, Andrei and Lisencu, Carmen and Trifa, Adrian Pavel and Balacescu, Ovidiu and Filip, Madalina and Miclaus, Maria and Catana, Andreea and Vlad, Catalin and Achimas-Cadariu, Patriciu},
  title = {Real-World Eligibility for Germline Multigene Panel Testing in Breast Cancer: An Evaluation of Current Testing Criteria},
  journal = {Diagnostics},
  year = {2026},
  volume = {16},
  number = {14},
  pages = {2244},
  doi = {10.3390/diagnostics16142244}
}
Kostenlos starten →